# Selzentry (maraviroc) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/maraviroc

> The FDA approved Selzentry (maraviroc), sponsored by GSK plc (GSK), on November 4, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Selzentry (maraviroc) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### November 4, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208984 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20161104, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product SELZENTRY (MARAVIROC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208984%22

### October 30, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208984 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20201030, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product SELZENTRY (MARAVIROC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208984%22
- openFDA Drugs@FDA: "NDA022128 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20201030, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product SELZENTRY (MARAVIROC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022128%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/maraviroc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Selzentry (maraviroc) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/maraviroc

```bibtex
@misc{secapidev_pdufa_maraviroc_20261116,
  title        = {Selzentry (maraviroc) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/maraviroc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_maraviroc_20261116","title":"Selzentry (maraviroc) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/maraviroc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
